CLAIMS

What is claimed is:

1. Use of 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of vitiligo in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject in need thereof.

2. The use of claim 1, wherein the therapeutically effective amount is selected from the group consisting of 10, 30, 50, 100 or 200 mg QD.

3. The use of any one of claims 1 to 2, wherein the medicament is to be administered to the subject for a maintenance period of up to 20 weeks following the induction period.

4. The use of any one of claims 1 to 3, wherein the subject has a body surface area involvement fo 4- 50%.

5. The use of any one of claims 1 to 3, wherein the subject achieves a percent change from baseline for local read facial Vitiligo Area Scoring Index of at least about -15%.

6. The use of any one of claims 1 to 3, wherein the subject achieves a 75% reduction in F-VASI from baseline at week 24.

7. The use of any one of claims 1 to 3, further comprising administering to the subject concurrent or subsequent treatment with narrow band ultraviolet B radiation add on therapy.

8. The use of claim 7, wherein the narrow band ultraviolet B radiation add on therapy is to be administered for at least 24 weeks.

9. The use of claim 7, whereby the subject achieves a percent change from baseline for local facial Vitiligo Area Scoring Index of up to between about -17% and about -30% at week 24 and between about -40% and about -80% at week 48.

10. The use of any one of claims 1 to 9, wherein the therapeutically effective amount is 10 mg QD.

11. The use according to any one of claims 1 to 9, wherein the therapeutically effective amount is 30 mg QD.

12. The use of any one of claims 1 to 9, wherein the therapeutically effective amount is 50 mg QD.

13. The use of any one of claims 1 to 9, wherein the therapeutically effective amount is 100 mg QD.

14. The use of any one of claims 1 to 9, wherein the therapeutically effective amount during the induction period is 50mg QD.

15. The use of any one of claims 1 to 9, wherein the therapeutically effective amount during the induction period is 100 mg QD.

16. Use of the compound 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of vitiligo according to any one of claims 1 to 15.

17. The compound 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof, for use in the treatment of vitiligo according to any one of claims 1 to 15.